Key Takeaways
- • Spire Healthcare Group has agreed to a recommended take-private by Tulip UK Bidco Limited, a newly formed consortium vehicle backed by Toscafund Asset Management, Three Hills (THCP Advisory), and Ares Management, at 250 pence per share in cash.
- • The transaction values Spire's fully diluted equity at approximately £1.03 billion and implies an enterprise value of roughly £2.31 billion, representing a 66.2% premium to the May 13 closing price of 150.4 pence per share.
- • Spire's board unanimously recommended the offer following an eight-month strategic review process that contacted more than 60 potential buyers; the Toscafund-led bid was the only formal proposal the board deemed sufficiently attractive.
- • Irrevocable undertakings from shareholders representing approximately 53.4% of issued ordinary share capital support the deal, which remains subject to shareholder, court, and regulatory approvals through a court-sanctioned scheme of arrangement.
- • Closing is expected in Q4 2026 or Q1 2027; the transaction includes planned leadership changes, with CEO Justin Ash retiring as part of the take-private restructuring.
Summary
Spire Healthcare Group, a FTSE 250 independent hospital operator, has agreed to a recommended cash acquisition by Tulip UK Bidco Limited, a specially formed acquisition vehicle backed by a three-part consortium. The sponsors—Toscafund Asset Management, Three Hills (THCP Advisory), and Ares Management—will collectively acquire the company at 250 pence per ordinary share in an all-cash transaction.
The deal values Spire's fully diluted equity at approximately £1.03 billion, with an implied enterprise value of roughly £2.31 billion. The 250 pence offer price delivers a 66.2% premium to the May 13 closing price of 150.4 pence, the last business day before market disclosure of a potential offer. This substantial premium reflects the consortium's assessment of Spire's strategic value as a consolidation opportunity in the UK independent hospital sector.
The transaction follows an eight-month strategic review process initiated by Spire's board, during which the company contacted more than 60 potential buyers. Despite this broad outreach, Tulip UK Bidco's proposal was the only formal bid that the board unanimously judged sufficiently attractive to recommend to shareholders. Backing for the offer is demonstrated through irrevocable undertakings covering approximately 53.4% of the company's issued ordinary share capital, providing a substantial foundation for deal completion.
Implementation will proceed via a court-sanctioned scheme of arrangement, a structure commonly used in UK takeovers that provides statutory protections and regulatory oversight. The transaction remains conditional on shareholder approval, court sanctioning, and relevant regulatory clearances. Management changes are also envisaged, with CEO Justin Ash planning his retirement as part of the acquisition transition. The consortium expects to close the transaction in the fourth quarter of 2026 or first quarter of 2027, subject to satisfaction of all outstanding conditions and approvals.
The deal values Spire's fully diluted equity at approximately £1.03 billion, with an implied enterprise value of roughly £2.31 billion. The 250 pence offer price delivers a 66.2% premium to the May 13 closing price of 150.4 pence, the last business day before market disclosure of a potential offer. This substantial premium reflects the consortium's assessment of Spire's strategic value as a consolidation opportunity in the UK independent hospital sector.
The transaction follows an eight-month strategic review process initiated by Spire's board, during which the company contacted more than 60 potential buyers. Despite this broad outreach, Tulip UK Bidco's proposal was the only formal bid that the board unanimously judged sufficiently attractive to recommend to shareholders. Backing for the offer is demonstrated through irrevocable undertakings covering approximately 53.4% of the company's issued ordinary share capital, providing a substantial foundation for deal completion.
Implementation will proceed via a court-sanctioned scheme of arrangement, a structure commonly used in UK takeovers that provides statutory protections and regulatory oversight. The transaction remains conditional on shareholder approval, court sanctioning, and relevant regulatory clearances. Management changes are also envisaged, with CEO Justin Ash planning his retirement as part of the acquisition transition. The consortium expects to close the transaction in the fourth quarter of 2026 or first quarter of 2027, subject to satisfaction of all outstanding conditions and approvals.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.